Several other equities research analysts have also commented on SNY. UBS Group boosted their price target on shares of Sanofi from €118.00 ($121.65) to €119.00 ($122.68) and gave the stock a buy rating in a report on Tuesday, June 7th. Deutsche Bank Aktiengesellschaft lifted their target price on shares of Sanofi from €85.00 ($87.63) to €90.00 ($92.78) and gave the stock a sell rating in a research note on Friday. SVB Leerink started coverage on shares of Sanofi in a research note on Monday, May 23rd. They set an outperform rating on the stock. Barclays lifted their target price on shares of Sanofi from €90.00 ($92.78) to €105.00 ($108.25) in a research note on Thursday, April 14th. Finally, Guggenheim boosted their price target on shares of Sanofi from €121.00 ($124.74) to €127.00 ($130.93) in a research report on Monday, May 2nd. One analyst has rated the stock with a sell rating and eight have given a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of Moderate Buy and an average price target of $111.14.
Sanofi Price Performance
Shares of NASDAQ SNY opened at $48.90 on Monday. The firm has a market cap of $123.76 billion, a PE ratio of 16.25, a PEG ratio of 1.23 and a beta of 0.48. The firm has a fifty day moving average of $51.32 and a 200 day moving average of $52.16. The company has a debt-to-equity ratio of 0.22, a quick ratio of 0.34 and a current ratio of 1.29. Sanofi has a one year low of $46.92 and a one year high of $58.10.
Institutional Trading of Sanofi
Sanofi Company Profile
Sanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company provides specialty care products, including human monoclonal antibodies; products for multiple sclerosis, neurology, other inflammatory diseases, immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes; and cardiovascular and established prescription products.
- Get a free copy of the StockNews.com research report on Sanofi (SNY)
- MarketBeat Podcast: Find Investing Opportunities For The Rest of 2022
- Deep Value High Yield Newell Brands Is Ready To Bottom
- The Colgate-Palmolive Growth Outlook Brightens
- These Stocks Outperformed Last Time There Was A Recession
- Does Rivian’s Stock Still Have A Future?
Want More Great Investing Ideas?
- Bear Market Game Plan!
- The 10 Best Stocks to Own in 2022
- 7 Stocks to Buy and Hold Forever
- 3 Stocks to DOUBLE This Year
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.